Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services
CAI•Revenue growth drivers
- Molecular profiling services: Revenue growth was driven primarily by a 55% rise in molecular profiling services revenue, supported by higher clinical case volume and ASP improvements.
- Clinical case volume: Clinical case volume rose 18% year over year to about 59,200, contributing to revenue growth.
- Gross margin: Gross margin rose to 68%, up 500 basis points from the prior year, attributed to higher case volume and ASP improvements.
Guidance raised for 2026
Caris raised its 2026 revenue guidance to $1.03 billion-$1.04 billion, up 27%-28% year over year.
The company also reaffirmed 2026 clinical therapy selection volume growth of about 20%.
Q2 revenue and loss improve
Caris Life Sciences said second-quarter revenue rose 45% year over year, driven by molecular profiling services.
The US molecular diagnostics firm narrowed its net loss to from a year earlier.
